Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

R B Verheijen; E L Swart; J H Beijnen; J H M Schellens; A D R Huitema; N Steeghs

doi:10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

R B Verheijen, E L Swart, J H Beijnen, J H M Schellens, A D R Huitema, N Steeghs

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

Abstract

In the original publication of the article, the second author name has been misspelled.

Original language	English
Article number	163
Pages (from-to)	1
Number of pages	1
Journal	Cancer Chemotherapy and Pharmacology
Volume	86
Issue number	1
Early online date	11 Jun 2020
DOIs	https://doi.org/10.1007/s00280-020-04090-4
Publication status	Published - Jul 2020

Access to Document

10.1007/s00280-020-04090-4

Fingerprint

Dive into the research topics of 'Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)'. Together they form a unique fingerprint.

Cite this

Verheijen, R. B., Swart, E. L., Beijnen, J. H., Schellens, J. H. M., Huitema, A. D. R., & Steeghs, N. (2020). Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). Cancer Chemotherapy and Pharmacology, 86(1), 1. Article 163. https://doi.org/10.1007/s00280-020-04090-4

@article{d469a6928f6d4f968da76a1de69fcff7,

title = "Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)",

abstract = "In the original publication of the article, the second author name has been misspelled.",

author = "Verheijen, {R B} and Swart, {E L} and Beijnen, {J H} and Schellens, {J H M} and Huitema, {A D R} and N Steeghs",

year = "2020",

month = jul,

doi = "10.1007/s00280-020-04090-4",

language = "English",

volume = "86",

pages = "1",

journal = "Cancer Chemotherapy and Pharmacology",

issn = "0344-5704",

publisher = "Springer-Verlag",

number = "1",

}

Verheijen, RB, Swart, EL, Beijnen, JH, Schellens, JHM, Huitema, ADR & Steeghs, N 2020, 'Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)', Cancer Chemotherapy and Pharmacology, vol. 86, no. 1, 163, pp. 1. https://doi.org/10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). / Verheijen, R B; Swart, E L; Beijnen, J H et al.
In: Cancer Chemotherapy and Pharmacology, Vol. 86, No. 1, 163, 07.2020, p. 1.

Research output: Contribution to journal › Comment/Letter to the editor › Academic › peer-review

TY - JOUR

T1 - Correction to

T2 - Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

AU - Verheijen, R B

AU - Swart, E L

AU - Beijnen, J H

AU - Schellens, J H M

AU - Huitema, A D R

AU - Steeghs, N

PY - 2020/7

Y1 - 2020/7

N2 - In the original publication of the article, the second author name has been misspelled.

AB - In the original publication of the article, the second author name has been misspelled.

UR - http://www.scopus.com/inward/record.url?scp=85086340810&partnerID=8YFLogxK

U2 - 10.1007/s00280-020-04090-4

DO - 10.1007/s00280-020-04090-4

M3 - Comment/Letter to the editor

C2 - 32524189

SN - 0344-5704

VL - 86

SP - 1

JO - Cancer Chemotherapy and Pharmacology

JF - Cancer Chemotherapy and Pharmacology

IS - 1

M1 - 163

ER -

Verheijen RB, Swart EL, Beijnen JH, Schellens JHM, Huitema ADR , Steeghs N. Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x). Cancer Chemotherapy and Pharmacology. 2020 Jul;86(1):1. 163. Epub 2020 Jun 11. doi: 10.1007/s00280-020-04090-4

Correction to: Exposure-survival analyses of pazopanib in renal cell carcinoma and soft tissue sarcoma patients: opportunities for dose optimization (Cancer Chemotherapy and Pharmacology, (2017), 80, 6, (1171-1178), 10.1007/s00280-017-3463-x)

Abstract

Access to Document

Other files and links

Fingerprint

Cite this